535
Participants
Start Date
October 30, 2018
Primary Completion Date
June 4, 2024
Study Completion Date
July 10, 2026
TG-C
2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
Placebo Control
2 mL normal saline injection
Corey Hunter, New York
Jason Oh, New York
Alan Kivitz, Duncansville
Mehul Desai, Washington D.C.
Ronald Delanois, Baltimore
James Clark, Charlottesville
Mark Hermann, Danville
Brett Gilbert, Durham
Jeremy Hoff, Wilmington
Edward Tavel, Columbia
Eric Loudermilk, Greenville
Sandeep Vaid, Newnan
David Billmeier, Daytona Beach
Anand Patel, Winter Park
Mercedes Ponce De Leon, Miami
Aurelio Torres-Consuegra, Miami
Edgar Gonzalez, Miami
Richard Linn, Sunrise
Cathy Barnes, New Port Richey
Howard Chipman, Oldsmar
Jeffrey Davis, Birmingham
Bradly Goodman, Birmingham
Harvey Bowles, Nashville
Hythem Shadid, Oak Brook
Dennis Levinson, Chicago
Manish Jain, Chicago
Melvin Churchill, Lincoln
Adil Fatakia, Marrero
Yogesh Mittal, Tulsa
Haresh Boghara, DeSoto
Amr Morsy, Dallas
Subodh Bhuchar, Houston
Daneshvari Solanki, Bellaire
Brian MacGillivray, San Antonio
Aldo Maspons, El Paso
Angela Krull, Draper
John Hemmersmeier, South Ogden
Saima Chohan, Phoenix
Nebojsa Skrepnik, Tucson
Timothy Davis, Santa Monica
Tien-I Su, Whittier
Dan La, Covina
Scott Hacker, La Mesa
Arthur Mabaquiao, San Diego
Diraj Karnani, Apple Valley
Eric Grigsby, Napa
Lead Sponsor
Kolon TissueGene, Inc.
INDUSTRY